Analysis Reveals Heart-Related Side Effects of Hydroxychloroquine and Chloroquine

Wiley press release 25 Set 2020




As the antimalarial drugs hydroxychloroquine and chloroquine have drawn attention as potential therapies for COVID-19 and are being widely used off-label, it’s now more important than ever to have a thorough assessment of the safety of these medications. A recent analysis published in the British Journal of Clinical Pharmacology provides new insights.

In the analysis of real-world data from the Food and Drug Administration Adverse Events Reporting System, a global database of post-marketing safety reports, hydroxychloroquine and chloroquine were associated with higher rates of various cardiovascular problems, including life-threatening heart rhythm events, heart failure, and damage to the heart muscle itself (termed cardiomyopathy).

“Moreover, we show how these adverse events carry high risks for severe outcomes including death, even with standard doses of the drugs,” said senior author Elad Maor, MD, PhD, of Sheba Medical Center and Tel-Aviv University, in Israel. “The take-home message of our work is that physicians around the world should be careful when prescribing these drugs for off-label indications, especially for patients with cardiac disorders.”

 

Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14546

Ultima modifica il Venerdì, 25 Settembre 2020 09:22
Vota questo articolo
(0 Voti)

Lascia un commento

Assicurati di aver digitato tutte le informazioni richieste, evidenziate da un asterisco (*). Non è consentito codice HTML.

 

Scienzaonline con sottotitolo Sciencenew  - Periodico
Autorizzazioni del Tribunale di Roma – diffusioni:
telematica quotidiana 229/2006 del 08/06/2006
mensile per mezzo stampa 293/2003 del 07/07/2003
Scienceonline, Autorizzazione del Tribunale di Roma 228/2006 del 29/05/06
Pubblicato a Roma – Via A. De Viti de Marco, 50 – Direttore Responsabile Guido Donati

Photo Gallery